BPC-157, GHK-Cu and KPV after surgery

A common question in peptide communities goes something like this: "I stopped my stack a week before surgery. When can I restart, and will BPC-157, GHK-Cu, and KPV interfere with the inflammation that healing needs?" The short answer is that none of these three peptides has been tested in post-surgical human trials, so no one can give you a validated restart window^[1]. The longer answer requires separating what the animal literature actually says about each peptide's effect on inflammation from the popular claim that inflammation suppression always slows healing.

Why the inflammation question is more complicated than it sounds

Surgical healing moves through overlapping phases: an initial inflammatory phase (roughly days 1 to 4), a proliferative phase (days 4 to 21 in most soft-tissue wounds), and a remodelling phase that continues for months. The inflammatory phase is not an obstacle to healing. It recruits the immune cells that clear debris and the signalling molecules that kick off new-tissue formation^[2]. The concern about anti-inflammatory agents slowing healing comes from studies on systemic corticosteroids and NSAIDs at high doses, which can blunt the early inflammatory signal too broadly. Whether the peptides in this stack behave similarly is a separate question, and the evidence base for that question is thin.

The popular framing that 'peptides accelerate healing' assumes the mechanism is inflammation suppression. For at least two of the three peptides here, the animal data suggests something different: modulation of the inflammatory environment rather than wholesale suppression of it.

What the preclinical literature says about each peptide

BPC-157 is a 15-amino-acid synthetic peptide that has been studied in rat and mouse injury models since the early 1990s. A 2021 review in Frontiers in Pharmacology covering skin wounds, fistulas, muscle, bone, and corneal injury reports that BPC-157 influences the resolution of vascular constriction and clot formation in damaged tissue, and rapidly increases expression of genes including Akt1, Nos3, and Vegfa within minutes of application^[1]. The proposed mechanism is angiogenic, meaning it appears to promote new blood-vessel growth into damaged areas rather than directly suppressing inflammatory cytokines. Critically, all of this evidence is preclinical. There is no published randomised controlled trial of BPC-157 in post-surgical humans.

GHK-Cu (glycine-histidine-lysine copper) is a copper-binding tripeptide naturally present in human plasma, saliva, and urine. A 2018 review in the International Journal of Molecular Sciences reports that GHK-Cu stimulates collagen, elastin, and glycosaminoglycan synthesis and promotes wound healing across skin, lung, bone, liver, and stomach tissue in preclinical models^[2]. The same review notes that GHK-Cu suppresses NF-kB activity, the signalling hub that drives many inflammatory responses, but frames this as a regulatory effect on inflammation rather than blanket suppression. The clinical evidence base, particularly for systemic or injectable use, remains limited.

KPV (lysine-proline-valine) is a tripeptide fragment derived from alpha-MSH (alpha-melanocyte-stimulating hormone), a naturally occurring anti-inflammatory peptide. A 2025 review in the International Journal of Medical Sciences examining tripeptides in wound healing reports that KPV exerts anti-inflammatory effects and supports tissue repair, with KPV-loaded hydrogels reducing inflammation and promoting tissue regeneration in wound models^[3]. Like BPC-157 and GHK-Cu, KPV has no published post-surgical human trial data.

The honest picture on timing

The lack of human trial data means there is no evidence-based restart window for any of these three peptides after surgery. Pre-operative cessation guidelines for peptides are not standardised anywhere, and the one-week pre-op pause the community tends to cite is a convention, not a clinical recommendation. What does exist for some surgical peptides, such as synthetic analogues with clearer pharmacokinetics, are manufacturer-issued guidelines. For grey-market research peptides, those guidelines do not exist.

The usual clinical advice for any compound affecting coagulation, inflammation, or wound healing is to discuss timing with your surgeon and the clinician who manages your stack, because surgical context matters. Procedure type, wound size, depth, whether you are taking any conventional NSAIDs or corticosteroids alongside, and individual healing rate all affect the risk-benefit picture. That is a conversation that belongs in a consulting room, not on a forum. See the BPC-157 regulation and safety overview for the legal status picture by country.

The anecdotal signal and what it does not tell us

The Reddit thread that prompted this article describes someone who stopped peptides one week before buccal fat removal and reports minimal post-operative pain and swelling. This is Tier 3 evidence: a single self-reported case with no control condition, no blinding, no way to rule out surgical skill, individual healing variation, or the placebo effect. The report is consistent with the animal literature on these peptides, but it does not confirm anything.

Post-surgical swelling and pain vary enormously between individuals and procedures regardless of any pharmacological intervention. A good surgeon, clean incision technique, and individual anatomy account for a significant share of outcomes. Attribution is hard even in controlled studies. It is essentially impossible from a single unblinded case report.

What this means if you are planning surgery

Three practical points from the literature. First, the animal data suggests these peptides modulate rather than suppress the inflammatory environment, which makes the 'you'll interfere with healing' concern less obvious than it is for systemic corticosteroids, but this has not been tested in post-surgical humans. Second, none of these peptides is an approved medicine anywhere^[4], which means your surgeon and anaesthetist may have limited or no pharmacological data on interactions with surgical agents. Disclosure is the responsible approach. Third, if you are an athlete subject to WADA testing, BPC-157 is prohibited under S0 at all times, and a surgical recovery period does not create an exemption.

This article is for education. The decision about when to start or resume any compound around surgery belongs with the clinicians managing your care. PeptideMethods does not advise on dosing, sourcing, or timing. The full regulatory picture is on the BPC-157 peptide page.